Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria's common stock on May 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.16, which is equal to the closing price of Astria'

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart's potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (HAE) with dosing every 3 and 6 months have been published in the Annals of Allergy, Asthma & Immunology. "We are thrilled by our publication in the Annals of Allergy, Asthma & Immunology and the opportunity to provide additional information that affirms our belief in navenibart's potential to become the first-choice therapy for HAE," said Christoph

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Citizens Life Sciences Conference on Wednesday, May 7th at 10:30am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jmp65/atxs/1702976. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bri

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria's common stock on April 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.40, which is equal to the closing price of Astria'

-- ALPHA-ORBIT Pivotal Phase 3 Trial Evaluating Every 3- and Every 6-Month Administration of Navenibart (STAR-0215) in Hereditary Angioedema is Underway -- -- Initial Efficacy and Safety Data from Navenibart ALPHA-SOLAR Long-Term Extension Trial Expected Mid-2025 -- -- Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist, Ongoing with Initial Results Anticipated in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate updat

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria's common stock on March 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to five employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.10, which is equal to the closing price of Astria

-- Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people living with hereditary angioedema (HAE). Navenibart has the potential to provide rapid and sustained HAE attack prevention with a very low treatment burden and administration every 3 months (Q3M) and every 6 months (Q6M). "We believe that navenibart will deliver strong efficacy, low treatment burden, and favorab

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/cowen177/atxs/2050656. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical comp

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025. Markus Magerl, M.D., Professor of Dermatology and Allergy at the Charité Universitätsmedizin Berlin Institute of Allergology, will present the design of the global Phase 3 trial of navenibart in a presentation of poster number 617 titled, "ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 shares of Astria's common stock on February 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $7.43, which is equal to the closing price of Ast

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca

-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03

-- ALPHA-STAR Phase 1b/2 Trial in People with HAE Underway with Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Phase 1a Results Support STAR-0215's Target Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of up to 117 Days -- -- Ended 4Q 2022 with Cash, Cash Equivalents, and Short-term Investments of $226M, Expected Cash Runway Through H1 2025 -- -- Webcast Today at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for t

Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and full year 2022 financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.

-- Preliminary Results from Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Expected by Year-End 2022 -- -- Phase 1a Results Expected to Inform on STAR-0215's Profile to Prevent Attacks in Hereditary Angioedema -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We are on track to report preliminary results from our Phase 1a trial of STAR-0215 by the end of this year. The trial is assessing safety and

-- FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema -- -- Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 -- -- Company to Host a Virtual R&D Day on September 30 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. "We are thrilled to announce that we have initiated dosing in our Phase 1a trial of STAR-0215 whic

-- On Track to File IND Application for STAR-0215 Mid-Year -- -- Initial Phase 1a Clinical Results Anticipated by Year End 2022 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "We are excited to advance STAR-0215 to the clinic this year with the planned initiation of our Phase 1a study," said Jill C. Milne, Ph.D., Chief Executive Officer of Astria. "STAR-0215 was created with a clear vision aim

-- STAR-0215, in Development to Treat HAE, on Track for Initial Phase 1 Clinical Results Expected by Year End 2022 -- -- New Preclinical Data on STAR-0215 Demonstrating High Potency and Extended Plasma Half-Life -- -- Findings on Burdens of Disease and Treatment in HAE Support Substantial Need to Decrease Patient Burden -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. "Our new company name, Astria, embodies our commitment to put patients first in all that we do. Astria originates fro

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), will report third quarter 2021 financial results before the Nasdaq Global Market open on Wednesday, November 10, 2021. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Conference Call Dial-In Information: Participant Toll-Free Dial-In Number: (877) 388-2733 Participant International Dial-In Number: (541) 797-2984 Passcode: 3606309 Please specify to the operator that you